Dexcom and Companion Medical Announce Collaboration to Integrate Dexcom CGM Data and InPen™ Insulin Data

SAN DIEGO--(BUSINESS WIRE)--Jun. 6, 2019-- DexCom, Inc. (NASDAQ:DXCM) and Companion Medical, Inc. today announced a collaboration to enable a direct exchange of CGM data from Dexcom with insulin data from InPen™ into both companies’ software applications. This agreement is the first of its kind and paves the way for advanced diabetes decision support, an important tool for insulin users.

Dexcom and Companion Medical are working together to develop a seamless data transfer of both insulin and glucose information. This collaboration enables both companies to offer advanced features and algorithms to improve in-the-moment decisions for those managing their diabetes with multiple daily injections. Advanced decision support requires multiple inputs, including current glucose, glucose trend, carbohydrate intake, accurate insulin dosing and insulin-on-board.

“Dexcom is committed to helping people make better therapy decisions based on their glucose levels, and Companion is committed to helping people make better insulin dosing decisions. These decisions are synchronous to the person living with diabetes which provides a compelling opportunity for our teams to work together,” said Steve Pacelli, EVP of Strategy and Corporate Development at Dexcom.

“We are pleased to be partnering with Dexcom on this important mission. Improving outcomes for people on multiple daily injections requires bringing together the two critical factors of diabetes management -- glucose and insulin -- in real-time. We are the first two companies with the technology capable of providing an integrated solution," said Sean Saint, CEO of Companion Medical.

As a first step in this collaboration, Dexcom and Companion Medical will enable InPen users to display long-acting and rapid-acting insulin data in the Dexcom CLARITY Diabetes Management Software. Dexcom CGM data is currently available in the Companion Medical Insights by InPen report. This integration enables health care providers to access a combined, comprehensive view of a patient’s therapy plan, increasing the effectiveness of how and when patients should dose and paving the way for improved and transparent treatment decisions.

The InPen/CLARITY report integration will be launched and available for preview at the upcoming American Diabetes Association Conference in San Francisco. Both companies are actively developing their real-time integrated systems.

About DexCom, Inc.

DexCom, Inc., headquartered in San Diego, CA, is dedicated to helping people better manage their diabetes by developing and marketing continuous glucose monitoring (CGM) products and tools for adult and pediatric people with diabetes. With exceptional performance, comfort and lifestyle flexibility at the heart of its technology, users have consistently ranked DexCom highest in customer satisfaction and loyalty. For more information on the Dexcom CGM, visit

About Companion Medical, Inc.

Companion Medical is a leader in the development of advanced technology to improve diabetes care. InPen™, the first and only FDA-cleared smart insulin pen, combines an innovative diabetes management app with a Bluetooth® enabled pen injector to simplify the constant tracking, monitoring and calculating required for insulin therapy. InPen addresses many of the issues that people living with diabetes face on a daily basis, including missed insulin doses, miscalculated insulin doses and insulin stacking.

Source: DexCom, Inc.

Dexcom Investor Contact:
Steve Pacelli, 858-200-0200

Dexcom Press Contact:
James McIntosh, 619-884-2118

Companion Medical Media Contact:
Steve Lamar
(858) 522-0252